Profile photo Peter van de Ven

Peter van de Ven

Associate Professor

Strategic program(s):

Biography

I am an associate professor in clinical trial methodology and statistics working within the Department of Data Science and Biostatistics of the Julius Center where I lead the Clinical Trial Methodology & Statistical Consultation team. My interests lie in innovative clinical trial methodology (both development and application) and adaptive methods, trials-within cohorts and trials in rare diseases in particular. I am the Trial Methodology Lead for U-TRIAL and workpackage leader for the Adaptive Trial Platform WP in the ONCODE-ACCELERATOR growthfund project. I am the chair of the UMC Utrecht's internal DSMB.  I also act as a methodology assessor (seconded) for the Dutch Medicines Evaluation Board (College ter Beoordeling van Geneesmiddelen: CBG-MEB). 

From July 2009 until April 2021 I worked at the Amsterdam UMC location VUmc as a researcher, a statistical consultant and methodology member of the hospital's institutional review board (METc).

I hold a PhD degree in Statistics from Eindhoven University of Technology (2007), a M.A. degree in Health Psychology from Tilburg University (2003) and a M.Sc. degree in Engineering Mathematics from Eindhoven University of Technology (2001). I have held postdoctoral research positions at the Southampton Statistical Sciences Research Institute S3RI (2007-2008) and TNO Quality of Life (2008-2009).

Strategic program(s):

Contact

Research groups

Julius Center Research Program Cancer

Research aim

Our mission is to drive impactful innovation for cancer prevention, diagnosis, prognosis, treatment, and care through interdisciplinary research, fostering collaboration among researchers across disciplines within the Julius Center and beyond.

Go to group

Clinical trial methodology & statistical consultation

Research aim

We develop, evaluate, and apply innovative clinical trial designs and sound statistical methodology to efficiently obtain high-quality evidence on healthcare interventions, ultimately optimizing patient outcomes

Go to group

Recent publications

Onderzoek naar afbouw van stemmingsstabilisatoren vraagt om een andere studieopzet A. Dols, P. B. van der Meer, E. J. Regeer, P. van de Ven
Tijdschrift voor Psychiatrie, 2026, vol. 68, p.62-63
Haemorrhagic Safety Update of CLEAR-PATH Emilien C J Wegerif, Manon I Generaal, Linde J Vijn, Rutger M van den Bor, Peter M van de Ven, Michiel L Bots, Gert J de Borst, Çağdaş Ünlü
EJVES Vascular Forum, 2026, vol. 65, p.32-39
Ethics of Backfilling in Early-Phase Oncology Trials Marieke J Hollestelle, Rob Kessels, Peter M van de Ven, Rieke van der Graaf
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026, vol. 44, p.626-629
Innovative Oncology Trial Designs Rosa Giuliani, Nafsika Kronidou-Horst, Christina Yap, Aáron Sosa Mejia, Lada Leyens, Theodor Framke, Fergus Sweeney, Laurence Collette, Rachel Giles, Jan Bogaerts, Peter van de Ven, Stefan N Symeonides
Journal of Cancer Policy, 2025, vol. 47
Potential benefits of l-serine in children with GRIN2B loss-of-function variants Bibiche den Hollander, Marieke Rothuizen-Lindenschot, Hoang Lan Le, Jennifer R Ramautar, Annelieke R Müller, Lisa Geertjens, Frédéric M Vaz, Agnies M van Eeghen, Martina C Cornel, Bart A W Jacobs, Hilgo Bruining, Peter M van de Ven, Marion M Brands, Clara D van Karnebeek
Molecular Genetics and Metabolism, 2025, vol. 146
Overcoming treatment implementation barriers for individuals with rare diseases using single-case experimental designs Annelieke R. Müller, Bibiche den Hollander, Agnies M. van Eeghen, Peter M. van de Ven, Martina Cornel, Mieke van Haelst, Jan J. Sprengers, Hilgo Bruining, Marion M. Brands, Clara D. van Karnebeek
Genetics in Medicine, 2025, vol. 27

External positions

Lid commissiepoule ZONMW programma Goed Gebruik Geneesmiddelen - Commissielid voor ZONMW GGG programma in eerste instantie Grote Trials rondes - ZONMW

Member of review committees Development (since January 2022) and PIPELINE (since April 2024) - Reviewer of grant applications submitted to Dutch Cancer Society (KWF) - KWF

Expert statistical reviewer - Performing statistical reviews of manuscripts submitted to Diabetologia journal - Diabetologia

Methodology assessor - Assessing dossiers filed for marketing authorization application and providing scientific advice - Dutch Medicines Evaluation Board (CBG-MEB)